The morbidity and mortality of hypertension have increased in recent years,threatening human cardiovascular health and increasing the global health burden.Renal sympathetic denervation(RDN),which reduces blood pressure by inhibiting renal sympathetic nerve activity,is a promising and novel treatment for hypertension.Among them,catheter-based renal sympathetic denervation has already been studied in several large-scale clinical studies,and the long-term follow-up results have been published,which has triggered a new thinking about the long-term efficacy of RDN.Therefore,this article focuses on the long-term efficacy of RSD and its potential influencing factors,aiming to provide a reference for the clinical application of RDN.
维普
万方数据